Skip to main content
. 2019 Oct 14;37(34):3291–3299. doi: 10.1200/JCO.19.01389

FIG 2.

FIG 2.

Antitumor activity in patients with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) treated with pembrolizumab. Percent change from baseline in target lesion size for evaluable patients by central review in (A) KEYNOTE-013 and (B) KEYNOTE-170 and treatment exposure and duration of response in (C) KEYNOTE-013 and (D) KEYNOTE-170. Eighteen patients in KEYNOTE-013 and 40 patients in KEYNOTE-170 were evaluable (had at least 1 postbaseline disease imaging assessment). Patients had stable disease (SD) unless otherwise indicated. CR, complete response; PD, progressive disease; PR, partial response.